{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:11:14Z","timestamp":1777954274514,"version":"3.51.4"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017037","name":"Cepheid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017037","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Mother-to-child transmission accounts for most new hepatitis B (HBV) infections in high-burden regions globally. The World Health Organization recommends antiviral prophylaxis for pregnant women with high hepatitis B viral load levels, but access to viral load testing remains limited and untimely in many countries, due to centralized testing. We assessed the operational feasibility, accessibility, and cost of implementing the Xpert HBV DNA assay in antenatal care settings. This was a two-phase study at 10 high-volume hospitals across nine regions of Uganda. Phase I verified the diagnostic accuracy of Xpert HBV DNA assay against the COBAS Taqman platform, while Phase II assessed feasibility, usability, and cost of integrating PoC testing into routine antenatal care using GeneXpert systems. Quantitative data were extracted from facility registers, entered into ODK, and analysed using SPSS 19 and Excel. Qualitative data, consisting of feedback from study teams, were analysed thematically. Xpert HBV DNA assay demonstrated full concordance with the COBAS platform. Overall, 96.7% of samples were processed, 92% returned to providers, and 61% of mothers received their results on the same day. Of 181 pregnant women provided HBV DNA testing, 12% had viral loads &gt;200,000 IU\/mL, thus eligible for antiviral prophylaxis. Among pregnant women eligible for prophylaxis, 14 had received antiviral prophylaxis. Birth records were available for 15 pregnant women, and 73.3% of their newborns had received the hepatitis B birth dose vaccine. Coordination between ANC and laboratory services, including the timely dispatch of results to pregnant women, was generally smooth and enabled prompt decision-making. However, some challenges were reported, such as stockout of screening kits and competing testing priorities within laboratories. At USD 15.37 per test, its cost was comparable to centralized testing (USD 15.26), but it offered advantages such as reduced delays and fewer client visits. The Xpert platform offers a timely, accurate, operationally feasible solution for accessing hepatitis B antiviral prophylaxis or treatment, improving quality of care for hepatitis B-positive mothers. With rapid turnaround time and cost comparable to centralized testing, it presents a valuable tool for improving HBV prevention and treatment in Uganda and similar resource-limited settings.<\/jats:p>","DOI":"10.1371\/journal.pgph.0006380","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:38:32Z","timestamp":1777916312000},"page":"e0006380","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing hepatitis B diagnosis for mothers in a low-resource setting: A field pilot of Xpert point-of-care viral load testing in Ugandan antenatal clinics"],"prefix":"10.1371","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5717-8909","authenticated-orcid":true,"given":"Linda Kisaakye","family":"Nabitaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7143-5753","authenticated-orcid":true,"given":"Viola","family":"Kasone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-5896","authenticated-orcid":true,"given":"Emmanuel","family":"Olal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9634-3277","authenticated-orcid":true,"given":"Judith","family":"Kyokushaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Kasibante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Nambozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidarayaan","family":"Namakula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan Nabadda","family":"Ndidde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ponsiano","family":"Ocama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Ssewanyana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"pgph.0006380.ref001","unstructured":"Organization WH. Global hepatitis report 2024: action for access in low-and middle-income countries: World Health Organization; 2024."},{"key":"pgph.0006380.ref002","author":"UNAIDS","year":"2025"},{"key":"pgph.0006380.ref003","doi-asserted-by":"crossref","unstructured":"Organization WH. Hepatitis B vaccines: WHO position paper, July 2017\u2013Recommendations. Vaccine. 2019;37(2):223-5.","DOI":"10.1016\/j.vaccine.2017.07.046"},{"key":"pgph.0006380.ref004","unstructured":"Organization WH. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. Global health sector strategy on viral hepatitis 2016-2021 Towards ending viral hepatitis 2016."},{"key":"pgph.0006380.ref005","unstructured":"Organization WH. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030: World Health Organization; 2022."},{"key":"pgph.0006380.ref006","author":"D Puspasari","year":"2019"},{"key":"pgph.0006380.ref007","unstructured":"Organization WH. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection: World Health Organization; 2024."},{"issue":"1","key":"pgph.0006380.ref008","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12939-024-02109-3","article-title":"Incorporating an intersectional gender approach to improve access to maternal and child health screening services","volume":"23","author":"MR Arrivillaga","year":"2024","journal-title":"Int J Equity Health"},{"issue":"3","key":"pgph.0006380.ref009","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000000309","article-title":"Diagnostic delays and clinical decision making with centralized Xpert MTB\/RIF testing in Durban, South Africa","volume":"67","author":"GM Cohen","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pgph.0006380.ref010","doi-asserted-by":"crossref","unstructured":"Shiferaw MB, Yismaw G. Magnitude of delayed turnaround time of laboratory results in Amhara Public Health Institute, Bahir Dar, Ethiopia. BMC Health Services Research. 2019;19:1-11.","DOI":"10.1186\/s12913-019-4077-2"},{"key":"pgph.0006380.ref011","unstructured":"Mbogua J. Towards Elimination of Vertical Transmission of HIV: Utilisation of HIV and Sexual and Reproductive Health Interventions by Female Sex Workers in Kenya and South Africa: London School of Hygiene & Tropical Medicine; 2023."},{"key":"pgph.0006380.ref012","unstructured":"Ministry of Health U. Uganda population-based HIV impact assessment (UPHIA) 2016\u20132017. Final Report [Internet]. 2019."},{"key":"pgph.0006380.ref013","unstructured":"Uganda MoH. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. 2020."},{"key":"pgph.0006380.ref014","unstructured":"Uganda M. Guidelines for the Uganda National Health Laboratory Hub and Sample Transport Network. 9. Ministry of Health. 2017."},{"key":"pgph.0006380.ref015","unstructured":"Baliruno LN, Gidudu S, Nakigozi H, Elayeete S, Nsubuga F, Ario AR. Improvement of sample receipt turnaround time for HIV viral load using a continuous quality improvement approach, Kigezi, Uganda, April-September 2023. 2023."},{"key":"pgph.0006380.ref016","volume-title":"Implementation of hepatitis B screening into routine antenatal care to prevent mother-to-child transmission in rural Western Uganda. Open Forum Infectious Diseases","author":"S Thahir","year":"2023"},{"key":"pgph.0006380.ref017","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079579","article-title":"Advances in the management of hepatitis B","volume":"389","author":"R Rajbhandari","year":"2025","journal-title":"BMJ"},{"issue":"2","key":"pgph.0006380.ref018","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.4102\/ajlm.v9i2.1103","article-title":"Preparing national tiered laboratory systems and networks to advance diagnostics in Africa and meet the continent\u2019s health agenda: Insights into priority areas for improvement","volume":"9","author":"P Ondoa","year":"2020","journal-title":"Afr J Lab Med"},{"issue":"11","key":"pgph.0006380.ref019","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3390\/microorganisms12112273","article-title":"Real-Life Diagnostic Accuracy and Clinical Utility of Hepatitis B Virus (HBV) Nucleic Acid Testing Using the GeneXpert Point-of-Care Test System from Fresh Plasma and Dry Blood Spot Samples in The Gambia","volume":"12","author":"A Ceesay","year":"2024","journal-title":"Microorganisms"},{"issue":"2","key":"pgph.0006380.ref020","doi-asserted-by":"crossref","first-page":"114946","DOI":"10.1016\/j.diagmicrobio.2019.114946","article-title":"Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNA","volume":"96","author":"F Abravanel","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"pgph.0006380.ref021","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/diagnostics11020297","article-title":"Multicenter Evaluation of the Cepheid Xpert\u00ae HBV Viral Load Test","volume":"11","author":"F Marcuccilli","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"pgph.0006380.ref022","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy. World Health Organization 2020. Geneva. 2020."},{"issue":"9","key":"pgph.0006380.ref023","article-title":"Impact of Hepatitis B Virus Point-of-care DNA Viral Load Testing Compared With Laboratory-based Standard-of-care Approaches on Uptake of HBV Viral Load Testing, Treatment, and Turnaround Times: A Systematic Review and Meta-analysis","volume":"11","author":"S Gu","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"pgph.0006380.ref024","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cll.2023.02.006","article-title":"Point-of-Care Testing for Sexually Transmitted Infections","volume":"43","author":"AN Riegler","year":"2023","journal-title":"Clin Lab Med"},{"issue":"3","key":"pgph.0006380.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213865","article-title":"Performance and usability of Cepheid GeneXpert HIV-1 qualitative and quantitative assay in Kenya","volume":"14","author":"P Bwana","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"pgph.0006380.ref026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193577","article-title":"Multidisease testing for HIV and TB using the GeneXpert platform: A feasibility study in rural Zimbabwe","volume":"13","author":"Z Ndlovu","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"pgph.0006380.ref027","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac609","article-title":"Timeliness of Point-of-Care Viral Load Results Improves Human Immunodeficiency Virus Monitoring in Nigeria","volume":"76","author":"B Chaplin","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pgph.0006380.ref028","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000000978","article-title":"Diagnostic Accuracy of the Point-of-Care Xpert HIV-1 Viral Load Assay in a South African HIV Clinic","volume":"72","author":"NJ Garrett","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"pgph.0006380.ref029","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12960-020-0454-5","article-title":"Uganda\u2019s laboratory human resource in the era of global health initiatives: experiences, constraints and opportunities-an assessment of 100 facilities","volume":"18","author":"SN Kiwanuka","year":"2020","journal-title":"Hum Resour Health"},{"issue":"1","key":"pgph.0006380.ref030","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/diagnostics11010140","article-title":"Costs of Point-of-Care Viral Load Testing for Adults and Children Living with HIV in Kenya","volume":"11","author":"MA Bulterys","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"pgph.0006380.ref031","doi-asserted-by":"crossref","first-page":"114946","DOI":"10.1016\/j.diagmicrobio.2019.114946","article-title":"Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNA","volume":"96","author":"F Abravanel","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"pgph.0006380.ref032","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1002\/jmv.26392","article-title":"Rapid, random-access, and quantification of hepatitis B virus using the Cepheid Xpert HBV viral load assay","volume":"93","author":"AM Auzin","year":"2021","journal-title":"J Med Virol"},{"issue":"2","key":"pgph.0006380.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212421","article-title":"Routine surveillance for the identification of drug resistant Tuberculosis in Tanzania: A cross-sectional study of stakeholders\u2019 perceptions","volume":"14","author":"BE Doulla","year":"2019","journal-title":"PLoS One"},{"key":"pgph.0006380.ref034","doi-asserted-by":"crossref","first-page":"100846","DOI":"10.1016\/j.ijregi.2026.100846","article-title":"Maternal preparedness for uptake of newborn hepatitis B immunoprophylaxis at birth: Implications for preventing mother-to-child transmission in resource-limited settings","volume":"18","author":"VE Senoo-Dogbey","year":"2026","journal-title":"IJID Reg"},{"issue":"4","key":"pgph.0006380.ref035","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2471\/BLT.20.272559","article-title":"Eliminating mother-to-child transmission of human immunodeficiency virus, syphilis and hepatitis B in sub-Saharan Africa","volume":"99","author":"J Cohn","year":"2021","journal-title":"Bull World Health Organ"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0006380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:38:39Z","timestamp":1777916319000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0006380"}},"subtitle":[],"editor":[{"given":"Mustafa A","family":"Barbhuiya","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0006380","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]}}}